Article Text

This article has a correction. Please see:

PDF
Safety, efficacy and cross-protectivity of a live intranasal aerosol haemorrhagic septicaemia vaccine
  1. A. Myint, BVS,
  2. H. H. Nyunt, BVS1 and
  3. T.O. Jones, MBE, BVSc, CBiol, MIBiol, FRVCS2
  1. 1 Biologics Production Division, Livestock Breeding and Veterinary Department, Insein, Yangon 11011,Myanmar
  2. 2 Eaton Lodge, 10 Station Road, East Leake, Loughborough, Leicestershire LE12 6LQ
  1. Advanced Biologicals, 111 Sabe Lane, Htanbingon, Sawbwagyigone, Insein, Yangon 11013,Myanmar
  2. Advanced Biologicals, 111 Sabe Lane, Htanbingon, Sawbwagyigone, Insein, Yangon 11013,Myanmar

Abstract

The safety, efficacy and cross-protectivity of a live intranasal aerosol haemorrhagic septicaemia vaccine containing Pasteurella multocida serotype B:3,4 were tested in young cattle and buffaloes in Myanmar, where more than 1˙5 million animals had been inoculated with this vaccine between 1989 and 1999. A recommended dose of 2 × 107 viable organisms was used for the efficacy test. The administration of 100 times the recommended dose to 50 cattle and 39 buffalo calves was innocuous. Seven months after they were vaccinated, three of three buffaloes were protected and 12 months after they were vaccinated, three of four buffaloes were protected against a subcutaneous challenge with serotype B:2 which killed three of three unvaccinated buffaloes. Twelve months after they were vaccinated, eight of eight cattle survived a serotype B:2 challenge, which killed four of four unvaccinated controls. The vaccinated cattle had developed serum antibodies detectable by the passive mouse protection test. Indirect haemagglutination tests on sera taken from cattle 10 days and five weeks after they were vaccinated showed high titres of antibodies. The serum of vaccinated cattle cross-protected passively immunised mice against infection with P multocida serotypes E:2, F:3,4 and A:3,4.

    Statistics from Altmetric.com

      Request permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

      Linked Articles

      • Correction
        BMJ Publishing Group Limited